Che-Ming Teng
Overview
Explore the profile of Che-Ming Teng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
1839
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lai M, Lee H, Chuang H, Chang L, Tsai A, Chen M, et al.
J Med Chem
. 2023 Apr;
66(9):6436.
PMID: 37079573
No abstract available.
2.
Liu Y, Tu H, Wu C, Lai M, Yu S, Chao M, et al.
Eur J Med Chem
. 2021 May;
219:113428.
PMID: 33934008
A series of ring-opened dihydroxybenzamides have been designed and synthesized as heat shock protein 90 inhibitors. One of derivatives, compound 6b ((N-ethyl-2,4-dihydroxy-5-isopropyl-N-(pyridin-3-yl)benzamide)) demonstrated remarkable antiproliferative activity against in human KRAS...
3.
Chao M, Chu P, Chuang H, Shen F, Chou C, Hsu E, et al.
Oncotarget
. 2020 Apr;
11(12):1096.
PMID: 32256981
[This retracts the article DOI: 10.18632/oncotarget.6427.].
4.
Lin C, Huang H, Peng C, Lee Y, Wang H, Teng C, et al.
Toxicol Appl Pharmacol
. 2019 Dec;
387:114858.
PMID: 31843362
No abstract available.
5.
Chao M, Chang L, Tu H, Chang C, Lai M, Chen Y, et al.
Clin Epigenetics
. 2019 May;
11(1):85.
PMID: 31142371
Background: Oncogenic K-Ras signaling highly relies on the canonical Ras/MEK/ERK pathway to contribute to pancreatic cancer progression. However, numerous efforts of MEK inhibitors have failed to provide an optimal antitumor...
6.
Chao M, Chen T, Huang H, Chang Y, HuangFu W, Lee Y, et al.
Sci Rep
. 2017 Apr;
7:46134.
PMID: 28387249
Recent studies have revealed that cardiac glycosides, such as digitalis and digoxin, have anticancer activity and may serve as lead compounds for the development of cancer treatments. The poor prognosis...
7.
Chen M, Kuo Y, Hsu C, Chen Y, Shen C, Teng C, et al.
Sci Rep
. 2017 Apr;
7:46149.
PMID: 28387244
Patients with ovarian cancer are typically diagnosed at an advanced stage, resulting in poor prognosis since there are currently no effective early-detection screening tests for women at average-risk for ovarian...
8.
Chao M, Huang H, HuangFu W, Hsu K, Liu Y, Wu Y, et al.
Oncotarget
. 2017 Feb;
8(17):27772-27785.
PMID: 28186963
Despite great advances in the treatment of acute leukemia, a renaissance of current chemotherapy needs to be improved. The present study elucidates the underlying mechanism of a new synthetic quinoline...
9.
Sun H, Cui R, Zhou J, Teng K, Hsiao Y, Nakanishi K, et al.
Cancer Cell
. 2016 Nov;
30(5):723-736.
PMID: 27846390
MicroRNAs (miRNA) are mostly downregulated in cancer. However, the mechanism underlying this phenomenon and the precise consequence in tumorigenesis remain obscure. Here we show that ERK suppresses pre-miRNA export from...
10.
Huang H, Chao M, Li Y, Chang L, Chen C, Chen M, et al.
Sci Rep
. 2016 Aug;
6:31664.
PMID: 27526962
Developing new anticancer agents against ovarian cancer is an urgent medical need. MPT0G066, a novel synthetic arylsulfonamide compound, was shown to inhibit cell growth and decrease viability in human ovarian...